跳至主要内容
临床试验/JPRN-jRCT2080223838
JPRN-jRCT2080223838已完成3 期

A Phase III, Open-label, Multi-Center Study to Evaluate the long term Safety of nemolizumab in Japanese Atopic Dermatitis Patients with moderate to severe pruritus

Maruho Co.,Ltd.0 个研究点目标入组 97 人开始时间: 2018年3月13日最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
97

研究概览

简要总结

The study treatment was safe and well tolerated. Few clinically significant abnormalities of laboratory tests, vital signs or ECGs were noted in the study. The result of pruritus VAS indicated the improvement in AD until Week 52. The improvement tendency in AD continued after Week 52.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 13age old 至 ot applicable(—)
性别
All

入选标准

  • Atopic Dermatitis with moderate or severe pruritus patients

排除标准

  • - Patients with body weight <30.0kg
  • - Patients with Hepatitis B virus or hepatitis C virus infection
  • - Patients with Evidence of tuberculosis (TB) infection
  • - Patients with immune deficiency
  • - Pregnant or lactating women

研究者

相似试验

已完成
3 期
High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)Primary Immunodeficiency Disease
NCT01313507Octapharma21
已完成
3 期
Fosamprenavir Versus Other Protease InhibitorsInfection, Human Immunodeficiency Virus I
NCT00094523ViiV Healthcare314
已完成
3 期
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityBardet-Biedl SyndromePOMC Deficiency ObesityPCSK1 Deficiency ObesityLEPR Deficiency Obesity
NCT04966741Rhythm Pharmaceuticals, Inc.12
进行中(未招募)
1 期
Chronocort®, a slow release medicinal preparation of hydrocortisone, will be compared with currently used glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia seeking to assess its safety, tolerability and effectiveness.Congenital adrenal hyperplasia (CAH)is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, and androgen excess. Subjects with CAH are at risk of developing a number of clinical manifestations, such as obesity in children, insulin resistance, and polycystic ovaries, which may contribute to infertility in women with CAH. Oligomenorrhoea or amenorrhoea may be present in adolescence.MedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000012082
EUCTR2015-000711-40-DKDiurnal Ltd120
进行中(未招募)
1 期
Chronocort®, a slow release medicinal preparation of hydrocortisone, will be compared with currently used glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia seeking to assess its safety, tolerability and effectiveness.Congenital adrenal hyperplasia (CAH)is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, and androgen excess. Subjects with CAH are at risk of developing a number of clinical manifestations, such as obesity in children, insulin resistance, and polycystic ovaries, which may contribute to infertility in women with CAH. Oligomenorrhoea or amenorrhoea may be present in adolescence.MedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000012082
EUCTR2015-000711-40-SEDiurnal Ltd120